title: Vemurafenib-associated Dupuytren- and Ledderhose palmoplantar fibromatosis in metastatic melanoma patients.
abstract: BACKGROUND
  The BRAF-inhibitor vemurafenib, used in patients with metastatic melanoma, induces multiple cutaneous side-effects.
  
  
  OBJECTIVE
  The aim of this work was to evaluate the development of palmoplantar fibromatosis in a population of patients treated with the BRAF inhibitor vemurafenib.
  
  
  METHODS
  Between April 2011 and February 2013, we initiated a treatment with vemurafenib in 53 patients with an unresectable stage IIIC or stage IV melanoma. The patients were followed-up on a regular base to monitor possible side-effects.
  
  
  RESULTS
  A plantar or palmar fibromatosis was observed in five of 53 patients treated with vemurafenib. In four of these patients other risk factors for the development of palmoplantar fibromatosis were absent.
  
  
  CONCLUSIONS
  The BRAF-inhibitor vemurafenib might induce palmoplantar fibromatosis.
authors: Department of Dermatology, Universitair Ziekenhuis Brussel, (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, Brussels, Belgium.
authors: V
authors: V
authors: Vandersleyen
authors: Department of Dermatology, Universitair Ziekenhuis Brussel, (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, Brussels, Belgium.
authors: M
authors: M
authors: Grosber
authors: Department of Medical Oncology, Universitair Ziekenhuis Brussel, (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, Brussels, Belgium.
authors: S
authors: S
authors: Wilgenhof
authors: Department of In Vitro Toxicology and Dermato-Cosmetology, Center for Pharmaceutical Research, Vrije Universiteit Brussel, Brussels, Belgium.
authors: J
authors: J
authors: De Kock
authors: Department of Medical Oncology, Universitair Ziekenhuis Brussel, (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, Brussels, Belgium.
authors: B
authors: B
authors: Neyns
authors: Department of Dermatology, Universitair Ziekenhuis Brussel, (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, Brussels, Belgium.
authors: J
authors: J
authors: Gutermuth
mesh_terms: D000368:Aged; D004387:Dupuytren Contracture / Q000139:chemically induced*; D005260:Female; D005350:Fibroma; D005528:Foot / Q000473:pathology*; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009362:Neoplasm Metastasis; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D013449:Sulfonamides / Q000009:adverse effects*; D000077484:Vemurafenib
chemical_list: D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; D048493:Proto-Oncogene Proteins B-raf